Shares of Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) saw unusually-strong trading volume on Tuesday. Approximately 3,696 shares were traded during trading, an increase of 11% from the previous session’s volume of 3,328 shares. The stock last traded at $12.00 and had previously closed at $11.7750.
Bavarian Nordic Trading Up 2.3%
The company has a 50 day simple moving average of $10.85 and a 200-day simple moving average of $10.04. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of 12.19 and a beta of 1.25.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last issued its quarterly earnings results on Friday, August 21st. The company reported $0.46 EPS for the quarter. The company had revenue of $316.47 million for the quarter. Bavarian Nordic had a return on equity of 11.97% and a net margin of 24.36%.
Bavarian Nordic Company Profile
Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.
Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.
See Also
- Five stocks we like better than Bavarian Nordic
- Chip Stocks Are Sliding—Why Is Smart Money Buying?
- Adults Are Fueling a Toy Boom—These 4 Stocks Could Cash In
- Could Quantinuum’s Breakthrough Make Its Sell-Off a Bargain?
- Wired for Upside: Why Goldman Sachs Upgraded CoreWeave’s Battered Stock
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
